ACRX News and Press, AcelRx Pharmaceuticals Inc. From 04/27/23

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 PR Newswire HAYWARD, Calif. , April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development ...

2023-04-13 03:58:04 ET Summary AcelRx Pharmaceuticals sold its opioid business in March 2023 at terms that were substantially below my previous expectations. The company raised capital in December 2022, causing a roughly 50% dilution of existing shareholders on a fully diluted bas...

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals PR Newswire In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior...

2023-03-30 20:28:14 ET AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Results Conference Call March 30, 2023 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and...

2023-03-30 16:11:21 ET AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q4 GAAP EPS of $1.00 beats by $1.51 . Revenue of $0.25M (+1150.0% Y/Y) misses by $4.25M . Divestment of DSUVIA to Alora Pharmaceuticals expected to close the week of April 3, 2023 ...

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary NiyadȒ...

2023-03-29 14:10:56 ET AcelRx Pharmaceuticals ( NASDAQ: ACRX ) is scheduled to announce Q4 earnings results on Thursday, March 30th, after market close. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $4.5M (vs. $0.2M in prior year quarter). ...

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 PR Newswire HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the ...

2023-03-14 09:20:37 ET AcelRx Pharmaceuticals ( NASDAQ: ACRX ) gained 16% pre-market Tuesday after announcing an agreement to divest its FDA-approved pain therapy Dsuvia to Alpharetta, GA-based Alora Pharmaceuticals. Per the terms, AcelRx ( ACRX ) will be entitled to...

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals PR Newswire Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potenti...